In situ characterization of the tumor microenvironment.


Journal

Current opinion in biotechnology
ISSN: 1879-0429
Titre abrégé: Curr Opin Biotechnol
Pays: England
ID NLM: 9100492

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 14 04 2023
revised: 07 12 2023
accepted: 30 01 2024
medline: 18 3 2024
pubmed: 22 2 2024
entrez: 21 2 2024
Statut: ppublish

Résumé

The development of new therapies for cancer is underpinned by an increasing need to comprehensively characterize the tumor microenvironment (TME). While traditional approaches have relied on bulk or single-cell approaches, these are limited in their ability to provide cellular context. Deconvolution of the complex TME is fundamental to understanding tumor dynamics and treatment resistance. Spatially resolved characterization of the TME is likely to provide greater insights into the cellular architecture, tumor-immune cell interactions, receptor-ligand interactions, and cell niches. In turn, these aid in dictating the optimal way in which to target each patient's individual cancer. In this review, we discuss a number of cutting-edge in situ spatial profiling methods giving us new insights into tumor biology.

Identifiants

pubmed: 38382325
pii: S0958-1669(24)00019-3
doi: 10.1016/j.copbio.2024.103083
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103083

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Habib Sadeghirad (H)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.

Vahid Yaghoubi Naei (V)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia; School of Biomedical Engineering, University of Technology Sydney, NSW, Australia.

Ken O'Byrne (K)

Princess Alexandra Hospital, Woolloongabba, QLD, Australia.

Majid E Warkiani (ME)

School of Biomedical Engineering, University of Technology Sydney, NSW, Australia.

Arutha Kulasinghe (A)

Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Electronic address: arutha.kulasinghe@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH